Dapagliflozin safe, well tolerated among adults with frailty: DAPA-HF - Healio

The SGLT2 inhibitor dapagliflozin safely reduced risk for worsening HF or CV death among adults with HF with reduced ejection fraction compared with placebo regardless of frailty status, researchers reported.In a post hoc analysis of the DAPA-HF trial, resear…

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.Back to Healio The SGLT2 inhibitor dapagliflozin safely… [+3751 chars]

full article...